DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries ...

DexCom's stock has declined 35% since my last bearish article, validating my "Sell" rating, though past bearish calls were incorrect as the stock previously doubled and tripled. Q3 results showed ...

In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other high growth large cap stocks. BlackRock highlighted that its portfolio managers are broadly ...

1 Day DXCM 0.95% DJIA -0.14% S&P 500 0.41% Health Care/Life Sciences -3.49% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

DexCom (NASDAQ:DXCM) reported third-quarter earnings that surpassed analyst expectations, but the company's stock plummeted 16% as revenue growth slowed significantly. The continuous glucose ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2024 financial results after market close on Thursday, October 24, 2024.